MedPath

HEMERION THERAPEUTICS

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

phase_1_2
1 (100.0%)

An interventional, multicenter, and international phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intraoperative photodynamic therapy (PDT) with Pentalafen® drug and Heliance® Solution device in male and female patients 18 to 75 years of age with grade IV glioblastoma.

Phase 1/2
Not yet recruiting
Conditions
High-grade glioma Glioblastoma
First Posted Date
2025-06-16
Last Posted Date
2025-06-16
Lead Sponsor
Hemerion Therapeutics
Target Recruit Count
6
Registration Number
2025-520563-41-00
Locations
🇫🇷

Centre Hospitalier Universitaire De Lille, Lille Cedex, France

News

No news found
© Copyright 2025. All Rights Reserved by MedPath